Thin
1 / 1
Bremelanotide is a synthetic melanocortin receptor agonist. Originally developed as a tanning agent, it is a metabolite of the compound MT-I and was later found to promote sexual function. Unlike most medications for erectile dysfunction in men targeting hemodynamic issues, it regulates libido by acting directly on melanocortin receptors in the central nervous system, particularly the hypothalamus. Its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug, and it has potential therapeutic effects in both men and women. The drug is administered via subcutaneous injection.
In 2019, its branded drug Vyleesi was approved by the U.S. FDA for the treatment of acquired and generalized sexual interest/arousal disorders in premenopausal women.
Especially suitable for male patients who do not respond to or cannot use such drugs (e.g., due to contraindications to nitrates). Its mechanism of action is independent of the nitric oxide pathway.
A potential treatment for improving libido.
In addition to the approved indications, its efficacy for other types of female sexual dysfunction is still under investigation.
A possible coping strategy for sexual dysfunction side effects caused by SSRIs.
Its core potential lies in meeting unmet medical needs, providing an important alternative for patients who are unresponsive to or intolerant of existing first-line therapies (such as PDE5 inhibitors). In the field of female sexual dysfunction, it is one of the few approved drugs, giving it a first-mover advantage.
Its mechanism of regulating libido by acting on the central nervous system gives it a theoretical advantage in treating the core problem of "lack of sexual interest".
Future development may depend on expanding indications (especially approval for male indications), optimizing administration methods (such as developing more convenient nasal sprays), and increasing public and medical awareness and willingness to seek treatment for related diseases.
Key challenges include: side effects (the most common being nausea and flushing, as well as the risk of increased blood pressure, which limits use for some patients), route of administration (requiring subcutaneous injection, which is less convenient than oral medications), and market acceptance and education (underdiagnosis and stigma still exist in the field of sexual dysfunction).
Development had previously focused on intranasal formulations, but related research has been interrupted or progressed slowly. Currently, the developers are primarily focused on commercializing the product in the market for its approved female indications and exploring potential applications for other central nervous system-related diseases.
In summary, Bremelanotide is a drug with a unique mechanism of action that has been successfully marketed for specific female sexual dysfunctions. It still holds significant potential in the field of male sexual dysfunction. Its long-term success will depend on overcoming limitations related to administration inconvenience and side effects, and effectively demonstrating its unique value for patients who have failed PDE5 inhibitor therapy in a highly competitive market.
